Large scale blood group genotyping.
Determination of predicted blood group phenotype by determination of genotype has been performed since the 1990s. This evolved due to the rapid accrual of information surrounding the molecular basis of blood group antigen expression, which started in 1990 with ABO and RH systems and has now resulted in the molecular description of 28 of the 29 blood groups. Blood group genotyping is currently performed mostly for fetal blood group incompatibility and for assessment of multi-transfused patients. Both of these clinical scenarios are either dangerous or technically difficult, respectively to define serologically. With the simultaneous development of mass scale genotyping platforms it has now permitted the application of them to blood group genotype determination. In this paper, I describe some recently published work that has demonstrated that mass scale genotyping approaches are feasible. These approaches may lead to more effective management of blood stocks and patient cross-matching by reducing the dependence on serology during the time critical pre-transfusion phase. It is most probable that large scale studies, perhaps involving many European Union and North American based blood suppliers, may drive the introduction of this technology and convince red cell serologists that this approach may allow their work to be more focussed.
Avent
Neil D
ND
Centre for Research in Biomedicine, Bristol Genomics Research Institute, Faculty of Applied Sciences, University of the West of England, Bristol, United Kingdom. Neil.avent@uwe.ac.uk
D001789:Blood Group Antigens / Q000235:genetics*; D001792:Blood Platelets / Q000502:physiology; D005838:Genotype; D006801:Humans; D015336:Molecular Probe Techniques / Q000191:economics
D001789:Blood Group Antigens